从易于获得的苯胺和4-氰基噻唑合成了一系列新型的氯化噻苯达唑(6a - m),产率中等至良好。使用1 H NMR,13 C NMR,IR和质谱对所有合成的化合物进行全面表征。另外,化合物(6f)的结构通过单晶X射线衍射确认。另外,使用我们优化的条件对2-取代的苯并咪唑和2-苯基苯并噻唑的合成进行了研究,结果在本文中给出。
从易于获得的苯胺和4-氰基噻唑合成了一系列新型的氯化噻苯达唑(6a - m),产率中等至良好。使用1 H NMR,13 C NMR,IR和质谱对所有合成的化合物进行全面表征。另外,化合物(6f)的结构通过单晶X射线衍射确认。另外,使用我们优化的条件对2-取代的苯并咪唑和2-苯基苯并噻唑的合成进行了研究,结果在本文中给出。
synthesized and their antiinflammatory activities toward NLRP3 (nucleotide-binding domain leucine-rich repeat containing protein family,pyrin domain-containing 3,also known as cryopyrin or NALP3) inflammasome were evaluated in vitro. Two lead compounds, TBZ-09 and TBZ-21, were identified by antiproduction of IL-1β. In the second round of biological evaluation, based on the lead, 34 more compounds were synthesized
[EN] AN IMPROVED PROCESS FOR THE PREPARATION OF THIABENDAZOLE<br/>[FR] PROCÉDÉ PERFECTIONNÉ POUR LA PRÉPARATION DE THIABENDAZOLE
申请人:HIKAL LTD
公开号:WO2019016834A1
公开(公告)日:2019-01-24
The present invention relates to an improved process for preparing thiabendazole of formula (I) with high yield, high purity, in economical and commercially viable manner for agricultural and pharmaceutical use.
Metal-Mediated Inhibition of <i>Escherichia </i><i>c</i><i>oli</i> Methionine Aminopeptidase: Structure−Activity Relationships and Development of a Novel Scoring Function for Metal−Ligand Interactions
作者:Rolf Schiffmann、Alexander Neugebauer、Christian D. Klein
DOI:10.1021/jm050476z
日期:2006.1.1
We report the discovery of thiabendazole as a potent inhibitor (K-i = 0.4 mu M) of Escherichia coli methionine aminopeptidase (ecMetAP) and the synthesis and pharmacological evaluation of thiabendazole congeners with activity in the upper nanomolar range. Elucidation of the X-ray structure of ecMetAP in complex with thiabendazole and an unrelated inhibitor that was independently described by another group showed that that both compounds bind to an additional Coll ion at the entrance of the active site. This unexpected finding explains the inactivity of the compounds under in vivo conditions. It also allows us to discuss the structure-activity relationships of this series of compounds in a meaningful way, based upon docking runs with an auxiliary metal ion. We describe a new scoring function for the evaluation of metal-mediated inhibitor binding that, unlike the previously used scoring function implemented in the docking program, allows us to distinguish between active and inactive compounds. Finally, conclusions for the structure-based design of in vivo-active inhibitors of ecMetAP are drawn.
Synthesis and biological evaluation of thiabendazole derivatives as anti-angiogenesis and vascular disrupting agents
Thiabendazole, already approved by FDA for oral use as an anti-fungal and anti-helminthic drug since 1967, has recently been repurposed as a vascular disrupting agent. By optimization of the structure of the lead compound, we successfully identified compound TBZ-19 and the new derivative is over 100-fold more potent than the lead compound against the growth of four different cell lines ( A549, HCT-116, HepG2 and HUVECs). The most potent two candidates TBZ-07 and TBZ-19, exhibiting moderate inhibitory cell proliferation activity, were also verified as anti-angiogenesis and vascular disrupting agents. Therefore, TBZ-07 and TBZ-19 would be promising candidates with vasculature targeting activity and merit further development. (C) 2015 Elsevier Ltd. All rights reserved.